← Oncolytics Biotech Inc. (ONCY) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Oncolytics Biotech Inc. (ONCY)
Pharmaceutical Preparations · market cap $88M · as of 2026-07-14
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-11 (est.)
Earnings
Pipeline
3
programs
Upcoming events
2
next 90d+
Dossier
Ready
cached
Oncolytics Biotech (ONCY) is a 28-employee San Diego biotech developing pelareorep (REOLYSIN), an intravenously delivered immuno-oncolytic reovirus, across multiple solid tumor indications. The company has a $111M market cap at ~$0.93/share but holds only $5.5M in cash — implying roughly 2.3 months of runway — with a Phase 3 trial ongoing in metastatic/recurrent squamous cell carcinoma of the lung as the lead program. No recent binary catalysts have read out; the next scheduled event is an August 2026 earnings report.
The catalyst path
- 2026-11-11 (est.)Earningsimp 5/10
- 2027-07-30 (est.)Phase 2 · Pelareorepimp 7/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| Pelareorep | Phase 2 | Anal Cancer Metastatic |
| REOLYSIN | Phase 3 | Metastatic or Recurrent Squamous Cell Carcinoma of the Lung |
| REOLYSIN® | Phase 2 | Carcinoma, Non-small Cell Lung |
Price & technical context
3-month
-28.4%
6-month
-34.4%
12-month
-55.6%
52-wk range
$0.63–$1.42
vs 50-day MA
-19.6%
vs 200-day MA
-30.7%
Realized vol
76.6%
Max drawdown
-76.4%
Daily closes through 2026-10-02. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for ONCY (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 3 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.